The U.S. Food and Drug Administration (FDA) inspects both 503A and 503B compounding pharmacies to assess if procedures, practices and controls exist for the preparation of products in compliance with FDA requirements. Are you prepared? Join Eagle Analytical Services General Manager and Chief Technical Officer Ross Caputo, PhD, for this FREE webinar, which will help you understand the inspections procedure, provide detailed information regarding the areas in which investigators are trained to evaluate, and outline the inspection process and expectations from the FDA. The information is not intended to convey legal advice; its sole use is for educational purposes.
- Central Drug Compounding & Wellness Recommends Eagle Plates - April 16, 2021
- Paperless Sample Submissions – Effective May 3, 2021 - April 8, 2021
- The Woodlands Compounding Pharmacy Recommends Eagle Plates - April 7, 2021